L 762583
Latest Information Update: 23 Jan 2008
At a glance
- Originator Merck & Co
- Class Anti-inflammatories
- Mechanism of Action Nitric oxide synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 14 Dec 2000 No-Development-Reported for Undefined in USA (Unknown route)
- 10 Jul 1998 Preclinical development for Undefined in USA (Unknown route)